The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update
Open accessAbstract
Antimicrobial resistance is a major global concern. Tuberculosis (TB) strains resistant to rifampicin and other TB medicines challenge patient survival and public health. The World Health Organization (WHO) has published treatment guidelines for drug-resistant TB since 1997 and last updated them in 2016 based on reviews of aggregated and individual patient data from published and unpublished studies. An international expert panel formulated recommendations following the GRADE approach. The new WHO guidelines recommend a standardised 9–12 months shorter treatment regimen as first choice in patients with multidrug- or rifampicin-resistant TB (MDR/RR-TB) strains not resistant to fluoroquinolones or second-line injectable agents; resistance to these two classes of core second-line medicines is rapidly detectable with molecular diagnostics also approved by WHO in 2016. The composition of longer regimens for patients ineligible for the shorter regimen was modified. A first-ever meta-analysis of individual paediatric patient data allowed treatment recommendations for childhood MDR/RR-TB to be made. Delamanid is now also recommended in patients aged 6–17 years. Partial lung resection is a recommended option in MDR/RR-TB care. The 2016 revision highlighted the continued shortage of high-quality evidence and implementation research, and reiterated the need for clinical trials and best-practice studies to improve MDR/RR-TB patient treatment outcomes and strengthen policy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,451
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
Self-citationGRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables
Guyatt, G., Oxman, A. D., Akl, E. A., Kunz, R., Vist, G., Brozek, J., Norris, S., Falck-Ytter, Y., Glasziou, P., & deBeer, H. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.04.026 · Cited by 10,681
Uplekar, M., Weil, D., Lonnroth, K., Jaramillo, E., Lienhardt, C., Dias, H. M., Falzon, D., Floyd, K., Gargioni, G., Getahun, H., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60570-0 · Cited by 1,117
Self-citationWHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update
Falzon, D., Jaramillo, E., Schünemann, H. J., Arentz, M., Bauer, M., Bayona, J., Blanc, L., Caminero, J. A., Daley, C. L., Duncombe, C., et al. (2011) · European Respiratory Journal · doi:10.1183/09031936.00073611 · Cited by 1,100
Self-citationSchünemann, H. J., Wiercioch, W., Etxeandia, I., Falavigna, M., Santesso, N., Mustafa, R., Ventresca, M., Brignardello-Petersen, R., Laisaar, K.-T., Kowalski, S., et al. (2014) · Canadian Medical Association Journal · doi:10.1503/cmaj.131237 · Cited by 686
Self-citationShort, Highly Effective, and Inexpensive Standardized Treatment of Multidrug-resistant Tuberculosis
Van Deun, A., Maug, A. K. J., Salim, M. A. H., Das, P. K., Sarker, M. R., Daru, P., & Rieder, H. L. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201001-0077oc · Cited by 647
Linezolid for Treatment of Chronic Extensively Drug-Resistant Tuberculosis
Lee, M., Lee, J., Carroll, M. W., Choi, H., Min, S., Song, T., Via, L. E., Goldfeder, L. C., Kang, E., Jin, B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1201964 · Cited by 560
Ahuja, S. D., Ashkin, D., Avendano, M., Banerjee, R., Bauer, M., Bayona, J. N., Becerra, M. C., Benedetti, A., Burgos, M., Centis, R., et al. (2012) · PLoS Medicine · doi:10.1371/journal.pmed.1001300 · Cited by 535
Self-citationWright, A., Zignol, M., Van Deun, A., Falzon, D., Gerdes, S. R., Feldman, K., Hoffner, S., Drobniewski, F., Barrera, L., van Soolingen, D., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60331-7 · Cited by 385
Self-citationAung, K. J. M., Van Deun, A., Declercq, E., Sarker, M. R., Das, P. K., Hossain, M. A., & Rieder, H. L. (2014) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.14.0100 · Cited by 318
Erasing the World's Slow Stain: Strategies to Beat Multidrug-Resistant Tuberculosis
Dye, C., Williams, B. G., Espinal, M. A., & Raviglione, M. C. (2002) · Science · doi:10.1126/science.1063814 · Cited by 314
Piubello, A., Harouna, S. H., Souleymane, M. B., Boukary, I., Morou, S., Daouda, M., Hanki, Y., & Van Deun, A. (2014) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.13.0075 · Cited by 226
Guideline panels should not GRADE good practice statements
Guyatt, G. H., Schünemann, H. J., Djulbegovic, B., & Akl, E. A. (2015) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2014.12.011 · Cited by 201
Self-citationHigh effectiveness of a 12-month regimen for MDR-TB patients in Cameroon
Kuaban, C., Noeske, J., Rieder, H. L., Aït-Khaled, N., Abena Foe, J. L., & Trébucq, A. (2015) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.14.0535 · Cited by 197
Twenty Years of Global Surveillance of Antituberculosis-Drug Resistance
Matteo Zignol, E., Dean, A. S., Falzon, D., Gemert, W. V., Wright, A., Deun, A. V., Portaels, F., Laszlo, A., Espinal, M., Pablos-Méndez, A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmsr1512438 · Cited by 148
Self-citationNunn, A., Rusen, I. D., Deun, A. V., Torrea, G., Phillips, P. P. J., Chiang, C., Squire, S. B., Madan, J. J., & Meredith, S. K. (2014) · Trials · doi:10.1186/1745-6215-15-353 · Cited by 128
Multidrug-resistant tuberculosis around the world: what progress has been made?
Falzon, D., Mirzayev, F., Wares, F., Baena, I. G., Matteo Zignol, E., Nguyen, L. N., Weyer, K., Jaramillo, E., Floyd, K., & Raviglione, M. C. (2014) · European Respiratory Journal · doi:10.1183/09031936.00101814 · Cited by 128
Self-citationFox, G. J., Mitnick, C. D., Benedetti, A., Chan, E. D., Becerra, M. C., Chiang, C., Keshavjee, S. A., Koh, W., Shiraishi, Y., Viiklepp, P., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw002 · Cited by 82
Winters, N., Butler‐Laporte, G., & Menzies, D. (2015) · European Respiratory Journal · doi:10.1183/13993003.00649-2015 · Cited by 43
Nasser, S. M. U., Cooke, G., Kranzer, K., Norris, S. L., Olliaro, P., & Ford, N. P. (2014) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2014.11.006 · Cited by 38
Harris, R. C., Grandjean, L., Martin, L. J., Miller, A. J. P., Nkang, J.-E. N., Allen, V. B., Khan, M. S., Fielding, K., & Moore, D. (2016) · BMC Infectious Diseases · doi:10.1186/s12879-016-1524-0 · Cited by 33
Cited by
Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline
Nahid, P., Mase, S. R., Migliori, G. B., Sotgiu, G., Bothamley, G. H., Brozek, J. L., Cattamanchi, A., Cegielski, J. P., Chen, L., Daley, C. L., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201909-1874st · Cited by 462
Floyd, K., Glaziou, P., Zumla, A., & Raviglione, M. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30057-2 · Cited by 440
Tiberi, S., du Plessis, N., Walzl, G., Vjecha, M. J., Rao, M., Ntoumi, F., Mfinanga, S., Kapata, N., Mwaba, P., McHugh, T. D., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30110-5 · Cited by 396
Recent updates on drug resistance in Mycobacterium tuberculosis
Singh, R., Dwivedi, S. P., Gaharwar, U. S., Meena, R., Rajamani, P., & Prasad, T. (2020) · Journal of Applied Microbiology · doi:10.1111/jam.14478 · Cited by 337
Miotto, P., Tessema, B., Tagliani, E., Chindelevitch, L., Starks, A. M., Emerson, C., Hanna, D., Kim, P. S., Liwski, R., Zignol, M., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.01354-2017 · Cited by 327
Metadata
- Authors
- Falzon, D., Schünemann, H. J., Harausz, E., González-Angulo, L., Lienhardt, C., Jaramillo, E., & Weyer, K.
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2017-03
- Volume
- 49
- Issue
- 3
- Pages
- 1602308
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W2603888074
- Cited by
- 420
- References
- 22
- FWCI
- 40.72
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.